Literature DB >> 28493068

Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.

Georg Nübling1,2,3, M Schuberth4, K Feldmer5, A Giese6, L M Holdt7, D Teupser7, S Lorenzl4,5,8.   

Abstract

Limited cleavage promotes the aggregation propensity of protein tau in neurodegenerative tauopathies. Cathepsin S (CatS) is overexpressed in brains of patients suffering from tauopathies such as Alzheimer's disease (AD). Furthermore, CatS serum levels correlate with survival in the elderly. The current study investigates whether limited cleavage by CatS promotes tau aggregation, and whether CatS serum levels may correlate with disease severity in tauopathies. Oligomer formation of fluorescently labeled protein tau was monitored by single particle fluorescence spectroscopy after coincubation with CatS. Tau cleavage patterns were investigated by SDS-PAGE. For serum analyses, samples were collected from 42 patients with probable progressive supranuclear palsy (PSP) according to NINDS-PSP criteria. Disease severity was assessed by PSP rating scale (PSP-RS), PSP staging system (PSP-S) and Schwab and England Activities of Daily Living (SEADL). CatS, cystatin C (CysC) and interleukin 6 (IL-6) serum levels were determined by ELISA, ECLIA and turbidimetry, respectively. SDS-PAGE demonstrated a distinct cleavage pattern of protein tau after coincubation with CatS. Furthermore, tau oligomer formation was increased 2.4-fold (p < 0.05) after limited cleavage. Serum CatS and CysC levels did not correlate with disease severity in PSP. Of note, IL-6 correlated with PSP-S (r = 0.41; 95% CI 0.11-0.65; p = 0.008), SEADL (r = -0.37; 95% CI -0.61 to -0.06; p = 0.017) and the history and gait/midline subdomains of the PSP-RS. While CatS facilitates tau aggregation in vitro, serum levels of CatS appear not to correlate with disease severity. The observed correlation of IL-6 with disease severity warrants further investigation of inflammatory markers in PSP.

Entities:  

Keywords:  Biomarker; Cathepsin S; Interleukin 6; Limited cleavage; Oligomer; Progressive supranuclear palsy; Tau

Mesh:

Substances:

Year:  2017        PMID: 28493068     DOI: 10.1007/s00221-017-4978-4

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  23 in total

1.  Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Authors:  Julia Gerson; Diana L Castillo-Carranza; Urmi Sengupta; Riddhi Bodani; Donald S Prough; Douglas S DeWitt; Bridget E Hawkins; Rakez Kayed
Journal:  J Neurotrauma       Date:  2016-04-22       Impact factor: 5.269

2.  Proteolysis of prion protein by cathepsin S generates a soluble beta-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms.

Authors:  Oxana Polyakova; Denise Dear; Igor Stern; Stephen Martin; Elizabeth Hirst; Suleman Bawumia; Angus Nash; Guy Dodson; Igor Bronstein; Peter M Bayley
Journal:  Eur Biophys J       Date:  2008-09-24       Impact factor: 1.733

3.  Cerebrospinal fluid cathepsin B and S.

Authors:  Elin Nilsson; Constantin Bodolea; Torsten Gordh; Anders Larsson
Journal:  Neurol Sci       Date:  2012-03-23       Impact factor: 3.307

4.  Single particle analysis of tau oligomer formation induced by metal ions and organic solvents.

Authors:  Benedikt Bader; Georg Nübling; Anja Mehle; Simona Nobile; Hans Kretzschmar; Armin Giese
Journal:  Biochem Biophys Res Commun       Date:  2011-06-24       Impact factor: 3.575

5.  Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo.

Authors:  Julia E Gerson; Urmi Sengupta; Rakez Kayed
Journal:  Methods Mol Biol       Date:  2017

6.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

7.  Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Authors:  Y P Wang; J Biernat; M Pickhardt; E Mandelkow; E-M Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

8.  Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level.

Authors:  Georg Nübling; Benedikt Bader; Johannes Levin; Jenna Hildebrandt; Hans Kretzschmar; Armin Giese
Journal:  Mol Neurodegener       Date:  2012-07-23       Impact factor: 14.195

9.  The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.

Authors:  J A Gormley; S M Hegarty; A O'Grady; M R Stevenson; R E Burden; H L Barrett; C J Scott; J A Johnston; R H Wilson; E W Kay; P G Johnston; S A Olwill
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

10.  Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease.

Authors:  Shih-Yuan Chen; Ta-Fu Chen; Liang-Chuan Lai; Jen-Hau Chen; Yu Sun; Li-Li Wen; Ping-Keung Yip; Yi-Min Chu; Yen-Ching Chen
Journal:  J Neuroinflammation       Date:  2012-01-24       Impact factor: 8.322

View more
  3 in total

Review 1.  Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.

Authors:  Breandan R Quinn; Laura Yunes-Medina; Gail V W Johnson
Journal:  J Neurosci Res       Date:  2018-03-23       Impact factor: 4.164

Review 2.  Microglia: Friend and foe in tauopathy.

Authors:  Kristian F Odfalk; Kevin F Bieniek; Sarah C Hopp
Journal:  Prog Neurobiol       Date:  2022-06-14       Impact factor: 10.885

Review 3.  The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates.

Authors:  Edoardo Moretto; Skye Stuart; Sunaina Surana; Jose Norberto S Vargas; Giampietro Schiavo
Journal:  Front Cell Neurosci       Date:  2022-04-29       Impact factor: 6.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.